Kera Capital Partners Inc. Has $1.40 Million Stock Holdings in Abbott Laboratories $ABT

Kera Capital Partners Inc. raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 305.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,464 shares of the healthcare product maker’s stock after purchasing an additional 7,881 shares during the quarter. Kera Capital Partners Inc.’s holdings in Abbott Laboratories were worth $1,402,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. IMG Wealth Management Inc. raised its stake in shares of Abbott Laboratories by 759.1% in the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the last quarter. Anfield Capital Management LLC grew its stake in shares of Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories during the second quarter valued at about $32,000. Curio Wealth LLC boosted its holdings in Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock worth $42,000 after purchasing an additional 305 shares during the last quarter. Finally, Pineridge Advisors LLC increased its stake in Abbott Laboratories by 34.6% in the 2nd quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker’s stock valued at $43,000 after buying an additional 81 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on ABT. Sanford C. Bernstein upped their target price on Abbott Laboratories from $150.00 to $154.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Barclays raised their target price on Abbott Laboratories from $162.00 to $169.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. The Goldman Sachs Group boosted their price target on shares of Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Evercore ISI raised their price objective on shares of Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a report on Monday, January 5th. Finally, Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $147.68.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $124.30 on Wednesday. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The firm has a market capitalization of $216.15 billion, a price-to-earnings ratio of 15.58, a PEG ratio of 2.06 and a beta of 0.72. The company’s fifty day moving average price is $126.12 and its 200-day moving average price is $129.17.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.37 billion during the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter in the previous year, the company posted $1.21 EPS. Abbott Laboratories’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.0%. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio is 29.57%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.